← Back to Search

Monounsaturated Fatty Acid

Palmitoleic acid, 1,000 mg (Dose 2) for Obesity

N/A
Waitlist Available
Led By Saame R Shaikh, PhD
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 12
Awards & highlights

Study Summary

This study is evaluating whether a fatty acid may help reduce inflammation in overweight individuals.

Eligible Conditions
  • Obesity
  • Chronic Inflammation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean c-reactive protein circulating level
Secondary outcome measures
Mean HbA1c level
Mean circulating adiponectin level
Mean circulating cytokine IL-6 level
+5 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Palmitoleic acid, 500 mg (Dose 1)Experimental Treatment1 Intervention
POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
Group II: Palmitoleic acid, 1,000 mg (Dose 2)Experimental Treatment1 Intervention
POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
Group III: PlaceboPlacebo Group1 Intervention
The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Palmitoleic acid, 500 mg (Dose 1)
2019
N/A
~130
Palmitoleic acid, 1,000 mg (Dose 2)
2019
N/A
~130

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,502 Previous Clinical Trials
4,186,619 Total Patients Enrolled
65 Trials studying Obesity
58,054 Patients Enrolled for Obesity
Organic TechnologiesUNKNOWN
Saame R Shaikh, PhDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
1 Previous Clinical Trials
24 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
CellJournal
Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity
Schirmer, Melanie, Sanne P. Smeekens, Hera Vlamakis, Martin Jaeger, Marije Oosting, Eric A. Franzosa, Rob ter Horst, et al.. 2016. “Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity”. Cell. Elsevier BV. doi:10.1016/j.cell.2016.10.020.
clinicaltrials.govStudy
Effect of Palmitoleic Acid on C-reactive Protein
2019. "Effect of Palmitoleic Acid on C-reactive Protein". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03625427.
~22 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top